Advantages of isovolemic large-volume erythrocytapheresis as a rapidly effective and long-lasting treatment modality for red blood cell depletion in patients with polycythemia vera
| Autor: | K. W. Rumpf, D. Krieter, T. Liersch, W. Kaboth, U. Kaboth, K. Vehmeyer |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Erythrocytapheresis
medicine.medical_specialty medicine.medical_treatment 030204 cardiovascular system & hematology Gastroenterology 03 medical and health sciences 0302 clinical medicine Polycythemia vera Phlebotomy hemic and lymphatic diseases Internal medicine medicine Humans Erythroid Progenitor Cells Polycythemia Vera Erythroid Precursor Cells Chemotherapy Acute leukemia business.industry General Medicine Iron deficiency medicine.disease 3. Good health Surgery Cytapheresis Red blood cell medicine.anatomical_structure Treatment Outcome Hematocrit business 030215 immunology |
| Zdroj: | Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis. 1(2) |
| ISSN: | 1091-6660 |
| Popis: | Long-term survival of patients with polycythemia vera (PV) is essentially determined by the ability to reduce the risk of thromboembolic complications resulting from the altered rheological conditions by the high red blood cell (RBC) mass of these patients. RBC depletion to normal hematocrit (Hct) values is the first line therapy and should be preferred to chemotherapy (or P32) because of the long-term risk of acute leukemia or other secondary malignancies. RBC depletion is accomplished much more effectively and rapidly by erythrocytapheresis (EA) than by repeated phlebotomies and has been shown to be well tolerated and accepted by the patients (8). The main indications for EA for a PV patient (often newly diagnosed) are high risk Hct values of >55–60% that can be reduced to the normal range within 1–2 h. The long-lasting effect (median interval between 2 EA treatments: ca. 6 months) is partially the result of the massive loss of iron, a growth factor for erythropoesis. This has been shown by in vitro studies in erythroid progenitor cells of PV patients before and after EA (11). The advantages and possible disadvantages of EA treatment are discussed.— |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text